1.875 0.005 (0.27%) | 02-19 12:12 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 2.49 | 1-year : | 2.8 |
Resists | First : | 2.13 | Second : | 2.4 |
Pivot price | 1.85 ![]() |
|||
Supports | First : | 1.71 | Second : | 1.42 |
MAs | MA(5) : | 1.87 ![]() |
MA(20) : | 1.9 ![]() |
MA(100) : | 2.2 ![]() |
MA(250) : | 2.22 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 47.9 ![]() |
D(3) : | 39.5 ![]() |
RSI | RSI(14): 40.9 ![]() |
|||
52-week | High : | 3.94 | Low : | 1.58 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ESPR ] has closed below upper band by 35.9%. Bollinger Bands are 81.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.93 - 1.94 | 1.94 - 1.95 |
Low: | 1.83 - 1.85 | 1.85 - 1.86 |
Close: | 1.85 - 1.87 | 1.87 - 1.89 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Wed, 19 Feb 2025
Zacks Research Has Pessimistic Outlook of ESPR Q3 Earnings - MarketBeat
Tue, 18 Feb 2025
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update - MarketBeat
Tue, 18 Feb 2025
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 - Yahoo Finance
Tue, 18 Feb 2025
Esperion Therapeutics (ESPR) Expected to Announce Earnings on Tuesday - MarketBeat
Thu, 02 Jan 2025
Esperion to Present at J.P. Morgan Healthcare Conference: Showcasing Non-Statin Breakthroughs - StockTitan
Thu, 26 Dec 2024
ZTS: 3 Healthcare Innovators with Analyst-Endorsed Upside - StockNews.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
Shares Out | 197 (M) |
Shares Float | 196 (M) |
Held by Insiders | 0.3 (%) |
Held by Institutions | 66.2 (%) |
Shares Short | 31,240 (K) |
Shares Short P.Month | 32,350 (K) |
EPS | -0.68 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -1.89 |
Profit Margin | -29.4 % |
Operating Margin | -31.1 % |
Return on Assets (ttm) | 3.8 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 52 % |
Gross Profit (p.s.) | 0.95 |
Sales Per Share | 1.49 |
EBITDA (p.s.) | 0.08 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -26 (M) |
Levered Free Cash Flow | -9 (M) |
PE Ratio | -2.8 |
PEG Ratio | 0 |
Price to Book value | -0.99 |
Price to Sales | 1.24 |
Price to Cash Flow | -14.32 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |